Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
JLP-2008
- Development stage
- Phase 1
- Lead developer
- Jeil Pharmaceutical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
JLP-2008 is a **small molecule sodium-glucose cotransporter 2 (SGLT2) inhibitor** developed by Jeil Pharmaceutical for the treatment of diabetes mellitus. SGLT2 inhibitors lower blood glucose levels by inhibiting the SGLT2 protein in the renal proximal tubules, which reduces glucose reabsorption and increases urinary glucose excretion. JLP-2008 is classified as an antihyperglycaemic agent and is a new molecular entity.
02
Targets
SGLT2 (Sodium-glucose cotransporter protein subunit 2)
Beyond the preview
Go deeper on JLP-2008.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on JLP-2008.